To further support this finding, we investigated the migratory response of AML cells after pre-incubation with AMD3465, a potent and selective CXCR4 antagonist and anti-TIMP-1 neutralizing Ab. This evidence concerns the gene CXCR4 and acute myeloid leukemia.